Short- and long-term outcomes of conversion minimally invasive esophagectomy versus open approach following induction therapy in cT4b esophageal cancer

View at publisher Summarise with VIRAT
Authors: Koshiro Ishiyama, Ryoko Nozaki, Ryota Kakuta, Shota Igaue, Eigo Akimoto, Daichi Utsunomiya, Daisuke Kurita, Yasuyuki Seto, Hiroyuki Daiko
Cited by: 0
References: 39

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Conversion surgery (CS) following induction therapy has emerged as a treatment option for patients with cT4b esophageal cancer previously considered unresectable. Minimally invasive approaches, including thoracoscopic and robot-assisted techniques, are increasingly applied in this setting. However, evidence comparing conversion minimally invasive esophagectomy (C-MIE) with conversion open esophagectomy (C-OE) remains limited. This single-center retrospective study included 66 patients with cT4b esophageal cancer who underwent CS after induction therapy between 2007 and 2023. Patients were classified into C-MIE (n = 41) or C-OE (n = 25) groups. Short-term outcomes, including operative time, blood loss, complications, and hospital stay, as well as long-term outcomes such as recurrence and survival, were compared. Prognostic factors were identified using multivariate Cox analysis. The C-MIE group showed markedly reduced intraoperative blood loss (79 vs. 470 mL, P < 0.001), lower incidence of anastomotic leakage (4.8 vs. 24%, P = 0.04), and shorter intensive care unit stay (3 vs. 4 days, P = 0.03) compared with the C-OE group. Three-year overall survival was higher in the C-MIE group (63.0 vs. 39.6%, P = 0.08), although not statistically significant. Multivariate analysis identified Clavien-Dindo grade ≥ IIIa (HR: 3.73, 95% CI: 1.81-7.67, P < 0.001) and ypStage ≥ III (HR: 3.51, 95% CI: 1.6-8.43, P = 0.001) as independent predictors of poorer survival. C-MIE showed a reduced risk but not significantly (HR: 0.79, 95% CI: 0.37-1.66; P = 0.537). C-MIE was associated with acceptable short-term outcomes and comparable long-term oncologic results to C-OE in patients with cT4b esophageal cancer responding to induction therapy.

Fields of Study & Subjects

Esophageal Cancer Research and Treatment Gastric Cancer Management and Outcomes Esophageal and GI Pathology

Publication details

Journal / source
Diseases of the Esophagus
Volume
39
Issue
2
Publication date
2 March 2026
Language
EN